TSRO - Tesaro, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
118.53
-1.78 (-1.48%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close120.31
Open119.67
Bid0.00 x 0
Ask0.00 x 0
Day's Range118.43 - 121.58
52 Week Range106.64 - 192.94
Volume461,200
Avg. Volume879,978
Market Cap6.42B
Beta2.20
PE Ratio (TTM)-11.91
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • TESARO, Inc. breached its 50 day moving average in a Bullish Manner : TSRO-US : October 13, 2017
    Capital Cube5 days ago

    TESARO, Inc. breached its 50 day moving average in a Bullish Manner : TSRO-US : October 13, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for TESARO, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bearish 50 ... Read more (Read more...)

  • See what the IHS Markit Score report has to say about TESARO Inc.
    Markit7 days ago

    See what the IHS Markit Score report has to say about TESARO Inc.

    Short interest is high for TSRO with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting TSRO. The net inflows of $2.53 billion over the last one-month into ETFs that hold TSRO are not among the highest of the last year and have been slowing.

  • Are Options Traders Betting on a Big Move in Tesaro (TSRO) Stock?
    Zacks13 days ago

    Are Options Traders Betting on a Big Move in Tesaro (TSRO) Stock?

    Investors in Tesaro (TSRO) need to pay close attention to the stock based on moves in the options market lately.

  • The Zacks Analyst Blog Highlights: Flexion Therapeutics, Alexion Pharmaceuticals, PTC Therapeutics, Johnson & Johnson and TESARO
    Zacks15 days ago

    The Zacks Analyst Blog Highlights: Flexion Therapeutics, Alexion Pharmaceuticals, PTC Therapeutics, Johnson & Johnson and TESARO

    The Zacks Analyst Blog Highlights: Flexion Therapeutics, Alexion Pharmaceuticals, PTC Therapeutics, Johnson & Johnson and TESARO

  • Capital Cube16 days ago

    TESARO, Inc. – Value Analysis (NASDAQ:TSRO) : October 2, 2017

    Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives TESARO, Inc. a score of 25. Our analysis is based on comparing TESARO, Inc. with the following peers – Clovis Oncology, Inc., ZIOPHARM Oncology, Inc., Amgen Inc., Dare Bioscience, Inc., Merck & Co., Inc., Bristol-Myers Squibb Company, Insys Therapeutics, Inc. and Pfizer Inc. (CLVS-US, ZIOP-US, AMGN-US, DARE-US, ... Read more (Read more...)

  • TESARO, Inc. breached its 50 day moving average in a Bullish Manner : TSRO-US : September 29, 2017
    Capital Cube19 days ago

    TESARO, Inc. breached its 50 day moving average in a Bullish Manner : TSRO-US : September 29, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for TESARO, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bearish 50 ... Read more (Read more...)

  • See what the IHS Markit Score report has to say about TESARO Inc.
    Markit21 days ago

    See what the IHS Markit Score report has to say about TESARO Inc.

    TESARO Inc NASDAQ/NGS:TSRO

  • Cancer Space Update: Mixed Week for Pfizer, Roche Falters
    Zacks26 days ago

    Cancer Space Update: Mixed Week for Pfizer, Roche Falters

    Roche again disappointed this week with two studies on Tecentriq being put on partial hold while Pfizer's Bavencio received approval in Europe. TESARO's Zejula moved a step closer to approval.

  • Biotech Stock Roundup: FDA Nod for First Cancer Biosimilar, HALO up on Deals, Raised Outlook
    Zacks28 days ago

    Biotech Stock Roundup: FDA Nod for First Cancer Biosimilar, HALO up on Deals, Raised Outlook

    Data presentations, regulatory updates and licensing deals were among the key highlights this week with the focus being on the FDA approval of the first cancer biosimilar - Amgen's (AMGN) Mvasi.

  • TESARO Ovarian Cancer Drug Zejula Gets Positive CHMP Opinion
    Zackslast month

    TESARO Ovarian Cancer Drug Zejula Gets Positive CHMP Opinion

    TESARO's (TSRO) marketing application for approval of its PARP-inhbitor Zejula as monotherapy for the maintenance treatment of ovarian cancer gets positive CHMP opinion.

  • Capital Cubelast month

    ETFs with exposure to TESARO, Inc. : September 12, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to TESARO, Inc. Here are 5 ETFs with the largest exposure to TSRO-US. Comparing the performance and risk of TESARO, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • See what the IHS Markit Score report has to say about TESARO Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about TESARO Inc.

    Short interest is high for TSRO with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting TSRO. ETFs that hold TSRO had net inflows of $1.56 billion over the last one-month.

  • TESARO, Inc. breached its 50 day moving average in a Bullish Manner : TSRO-US : September 1, 2017
    Capital Cube2 months ago

    TESARO, Inc. breached its 50 day moving average in a Bullish Manner : TSRO-US : September 1, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for TESARO, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bearish 50 ... Read more (Read more...)

  • Capital Cube2 months ago

    ETFs with exposure to TESARO, Inc. : September 1, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to TESARO, Inc. Here are 5 ETFs with the largest exposure to TSRO-US. Comparing the performance and risk of TESARO, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Motley Fool2 months ago

    We Got It Wrong With OPKO Health -- Now What?

    OPKO Health’s been dealt setbacks that have caused its shares to nose-dive, rather than head higher. Is that about to change?

  • See what the IHS Markit Score report has to say about TESARO Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about TESARO Inc.

    TESARO Inc NASDAQ/NGS:TSRO

  • TESARO, Inc. :TSRO-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
    Capital Cube2 months ago

    TESARO, Inc. :TSRO-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017

    Categories: Yahoo FinanceGet free summary analysis TESARO, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of TESARO, Inc. – Clovis Oncology, Inc., ZIOPHARM Oncology, Inc., Amgen Inc., Merck & Co., Inc., Bristol-Myers Squibb Company, Insys Therapeutics, Inc. and Pfizer Inc. (CLVS-US, ZIOP-US, AMGN-US, MRK-US, BMY-US, ... Read more (Read more...)

  • Barrons.com2 months ago

    Tesaro: Losing Its Edge?

    The FDA decided yesterday to expand the use of the ovarian cancer drug Lynparza, sold by AstraZeneca (AZN) and Merck (MRK). The two drugs belong to a class known as PARP inhibitors. Approved in 2014, AstraZeneca's Lynparza was the first such drug to make its way through the FDA.

  • Barrons.com2 months ago

    Ovarian Cancer Market Still Up For Grabs

    The Food and Drug Administration approved a broader label for AstraZeneca’s (AZN) breast cancer drug Lynparza to be used in ovarian cancer patients. Morgan Stanley’s Andrew Berens and his team are updating their models following the news, writing that he expects the three major players—AstraZeneca, Clovis Oncology (CLVS), and Tesaro (TSRO)—will likely split the market for second line (2L) treatment.

  • See what the IHS Markit Score report has to say about TESARO Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about TESARO Inc.

    Short interest is high for TSRO with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting TSRO. ETFs that hold TSRO had net inflows of $1.34 billion over the last one-month.

  • See what the IHS Markit Score report has to say about TESARO Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about TESARO Inc.

    TESARO Inc NASDAQ/NGS:TSRO

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of TSRO earnings conference call or presentation 8-Aug-17 8:15pm GMT

    Q2 2017 TESARO Inc Earnings Call

  • Barrons.com2 months ago

    Biotech: Why Clovis And Tesaro Look Well Positioned

    Morgan Stanley's Andrew Berens and his team have a note out on biotech, writing that investors should buy Clovis Oncology (CLVS) and Tesaro (TSRO) ahead of any labeling decision by the Food and Drug Administration for AstraZeneca's (AZN) Lynparza breast cancer drug. Berens writes that he expects the most likely outcome is that the FDA will limit the label BRCA patients--or at least have less promising results outside BRCA.

  • Associated Press2 months ago

    Tesaro reports 2Q loss

    The Waltham, Massachusetts-based company said it had a loss of $2.82 per share. The results did not meet Wall Street expectations. The average estimate of 12 analysts surveyed by Zacks Investment Research ...

  • Benzinga2 months ago

    A Biotech Binary Event Playbook: How To Play Clovis And Tesaro Ahead Of Label Decision

    Morgan Stanley said in a note Tuesday it would be buyers of Clovis Oncology Inc (NASDAQ: CLVS ) and TESARO Inc (NASDAQ: TSRO ) ahead of the Lynparza label decision. AstraZeneca plc (ADR) (NYSE: AZN )'s ...